Attached files
| file | filename |
|---|---|
| 8-K - 8-K - ATHENAHEALTH INC | athn-20121231x8k.htm |
| EX-99.2 - PREPARED REMARKS - ATHENAHEALTH INC | athnq42012earningsprepared.htm |
athenahealth, Inc. Reports Fourth Quarter and Full Year 2012 Results
Q4 2012 Financial Results
• | 26% Revenue Growth Over Fourth Quarter of 2011 |
• | GAAP Net Income of $5.9 Million, or $0.16 Per Diluted Share |
• | Non-GAAP Adjusted Net Income of $10.8 Million, or $0.29 Per Diluted Share |
Full Year 2012 Financial Results
• | 30% Revenue Growth Over Full Year 2011 |
• | GAAP Net Income of $18.7 Million, or $0.50 Per Diluted Share |
• | Non-GAAP Adjusted Net Income of $37.2 Million, or $1.00 Per Diluted Share |
WATERTOWN, MA – February 7, 2013 - athenahealth, Inc. (NASDAQ: ATHN) (the “Company,” “we,” or “athenahealth”), a leading provider of cloud-based electronic health record (EHR), practice management, and care coordination services to medical groups and health systems, today announced financial and operational results for the fourth quarter and full year 2012. The Company will conduct a conference call tomorrow, Friday, February 8, 2013, at 8:00 a.m. Eastern Time to discuss these results and management’s outlook for future financial and operational performance.
Total revenue for the three months ended December 31, 2012, was $116.3 million, compared to $92.5 million in the same period last year, an increase of 26%. Full year 2012 revenue was $422.3 million, compared to full year 2011 revenue of $324.1 million, an increase of 30%.
“2012 was a pivotal year for athenahealth. We delivered strong top and bottom line performance and made marked progress on our mission to be medical care givers' most trusted service,” said Jonathan Bush, the Company’s Chairman and Chief Executive Officer. “While information liquidity in health care is mostly an abstract concept, our effort to build a sustainable, market-based national health information backbone is slowly gaining traction. Our information services cover the life cycle of a claim, the chart, the patient relationship and the hospital admission, but they are still small. We have the right model and together with our nearly 40,000 forward-thinking providers who are tapped into our cloud-based network, we are slowly connecting the synapses of health care.”
For the three months ended December 31, 2012, Non-GAAP Adjusted Gross Margin was 63.4%, down from 64.2% in the same period last year, as the Company continues to invest in its newest service offering, athenaCoordinator®. Non-GAAP Adjusted EBITDA increased 31%, to $27.1 million, or 23.3% of total revenue, from Non-GAAP Adjusted EBITDA of $20.7 million, or 22.4% of total revenue, in the same period last year. For the three months ended December 31, 2012, GAAP net income was $5.9 million, or $0.16 per diluted share, compared to $5.3 million, or $0.15 per diluted share, in the same period last year. Non-GAAP Adjusted Net Income was $10.8 million, or $0.29 per diluted share, up from $9.3 million, or $0.26 per diluted share, in the same period last year. See “Use of Non-GAAP Financial Measures” below.
“The athenahealth team delivered another great year. We achieved our revenue growth goal of 30% for the 13th year in a row and continued our efforts to improve operational efficiencies across each of our service offerings,” said Tim Adams, the Company’s Chief Financial Officer. “Our investments in growth and innovation are a sign of our commitment to our 30% growth target and to our vision of becoming an information backbone that helps health care work as it should.”
For the year ended December 31, 2012, Non-GAAP Adjusted Gross Margin was 62.6%, down from 63.8% for full year 2011. Non-GAAP Adjusted EBITDA grew to $90.9 million, or 21.5% of total revenue
1
from Non-GAAP Adjusted EBITDA for 2011 of $70.6 million, or 21.8% of total revenue. For full year 2012, GAAP net income was $18.7 million, or $0.50 per diluted share. Non-GAAP Adjusted Net Income for the year was $37.2 million, or $1.00 per diluted share. See "Use of Non-GAAP Financial Measures" below.
Key metrics and milestones in the fourth quarter and full year 2012 included the following:
• | $2.5 billion in collections posted to client accounts in the fourth quarter of 2012, compared to $2.0 billion in the same quarter of 2011 |
• | $9.2 billion in collections posted to client accounts in all of 2012, compared to $7.3 billion in all of 2011 |
• | 36.4 average client Days in Accounts Receivable (DAR) in the fourth quarter of 2012, compared to 38.9 average client DAR in the same quarter of 2011 |
• | 39,752 active medical providers using athenaCollector® at December 31, 2012, 28,011 of whom were physicians, compared to 32,740 providers and 23,210 physicians at December 31, 2011 |
• | 10,926 active medical providers using athenaClinicals® at December 31, 2012, 7,949 of whom were physicians, compared to 6,525 providers and 4,662 physicians at December 31, 2011 |
• | 14,065 active medical providers using athenaCommunicator® at December 31, 2012, 10,153 of whom were physicians, compared to 5,830 providers and 4,098 physicians at December 31, 2011 |
As of December 31, 2012, the Company had cash, cash equivalents, and available-for-sale investments of $193.1 million. The Company does not have any outstanding debt obligations.
Use of Non-GAAP Financial Measures
In the Company’s earnings releases, conference calls, slide presentations, and webcasts, the Company may use or discuss non-GAAP financial measures, as defined by SEC Regulation G. The GAAP financial measure most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measure, are included in this press release after the consolidated financial statements. The Company’s earnings press releases containing such non-GAAP reconciliations can be found on the Investors section of the Company’s web site at http://www.athenahealth.com.
Conference Call Information
To participate in the Company’s live conference call and webcast, please dial 800-447-0521 (or 847-413-3238 for international calls) using conference code No. 34078406, or visit the Investors section of the Company’s web site at www.athenahealth.com. A replay will be available for one week following the conference call at 888-843-7419 (and 630-652-3042 for international calls) using conference code No. 34078406. A webcast replay will also be archived on the Company’s website.
About athenahealth
athenahealth is a leading provider of cloud-based Best in KLAS electronic health record (EHR), practice management, care coordination services to medical groups and health systems. athenahealth's mission is
2
to be the most trusted service to medical care givers, helping them do well, doing the right thing. For more information, please visit http://www.athenahealth.com/ or call (888) 652-8200.
Forward-Looking Statements
This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements reflecting management’s expectations for future financial and operational performance and operating expenditures, expected growth, and business outlook; statements regarding the benefits of the Company’s service offerings; statements regarding changes in the health care industry, including an increased emphasis on coordinated care and health information exchange, and the Company’s positioning in regard to those changes; and statements found under the Company’s “Reconciliation of Non-GAAP Financial Measures to Comparable GAAP Measures” section of this release. The forward-looking statements in this release do not constitute guarantees of future performance. These statements are neither promises nor guarantees, and are subject to a variety of risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things: the Company’s fluctuating operating results; the Company’s variable sales and implementation cycles, which may result in fluctuations in its quarterly results; risks associated with the acquisition and integration of companies and new technologies to achieve expected synergies; risks associated with its expectations regarding its ability to maintain profitability; the impact of increased sales and marketing expenditures, including whether increased expansion in revenues is attained and whether impact on margins and profitability is longer term than expected; changes in tax rates or exposure to additional tax liabilities; the highly competitive industry in which the Company operates and the relative immaturity of the market for its service offerings; and the evolving and complex governmental and regulatory compliance environment in which the Company and its clients operate. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances, or otherwise. For additional disclosure regarding these and other risks faced by the Company, please see the disclosures contained in its public filings with the Securities and Exchange Commission, available on the Investors section of the Company’s website at http://www.athenahealth.com and on the SEC’s website at http://www.sec.gov.
Contacts:
Dana Quattrochi
athenahealth (Investors)
(617) 402-1329
investorrelations@athenahealth.com
Holly Spring
athenahealth (Media)
(617) 402-1631
hspring@athenahealth.com
3
athenahealth, Inc.
CONSOLIDATED BALANCE SHEETS
(Unaudited, in thousands, except per share amounts)
December 31, 2012 | December 31, 2011 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 154,988 | $ | 57,781 | ||||
Short-term investments | 38,092 | 62,084 | ||||||
Current portion of restricted cash | 1,357 | — | ||||||
Accounts receivable - net | 61,916 | 49,038 | ||||||
Deferred tax assets | 6,907 | 5,245 | ||||||
Prepaid expenses and other current assets | 10,924 | 8,988 | ||||||
Total current assets | 274,184 | 183,136 | ||||||
Property and equipment - net | 54,035 | 52,275 | ||||||
Restricted cash | — | 5,007 | ||||||
Capitalized software costs - net | 16,050 | 6,974 | ||||||
Purchased intangibles - net | 21,561 | 20,052 | ||||||
Goodwill | 48,090 | 47,307 | ||||||
Deferred tax assets | 11,759 | 12,532 | ||||||
Investments and other assets | 2,773 | 21,503 | ||||||
Total assets | $ | 428,452 | $ | 348,786 | ||||
Liabilities & Stockholders’ Equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 1,733 | $ | 6,318 | ||||
Accrued compensation | 36,393 | 28,176 | ||||||
Accrued expenses | 19,683 | 17,774 | ||||||
Current portion of deferred revenue | 8,209 | 6,345 | ||||||
Current portion of deferred rent | 799 | 960 | ||||||
Total current liabilities | 66,817 | 59,573 | ||||||
Deferred rent, net of current portion | 2,854 | 2,932 | ||||||
Deferred revenue, net of current portion | 45,515 | 44,281 | ||||||
Other long-term liabilities | 1,618 | 5,529 | ||||||
Total liabilities | 116,804 | 112,315 | ||||||
Stockholders’ equity: | ||||||||
Preferred stock, $0.01 par value: 5,000 shares authorized; no shares issued and outstanding at December 31, 2012, and December 31, 2011, respectively | — | — | ||||||
Common stock, $0.01 par value: 125,000 shares authorized; 37,572 shares issued and 36,294 shares outstanding at December 31, 2012; 36,678 shares issued and 35,400 shares outstanding at December 31, 2011 | 376 | 367 | ||||||
Additional paid-in capital | 303,547 | 247,131 | ||||||
Treasury stock, at cost, 1,278 shares | (1,200 | ) | (1,200 | ) | ||||
Accumulated other comprehensive loss | (81 | ) | (101 | ) | ||||
Retained earnings (accumulated deficit) | 9,006 | (9,726 | ) | |||||
Total stockholders’ equity | 311,648 | 236,471 | ||||||
Total liabilities and stockholders’ equity | $ | 428,452 | $ | 348,786 | ||||
4
athenahealth, Inc.
CONSOLIDATED STATEMENTS OF INCOME
(Unaudited, in thousands, except per share amounts)
Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||||||||||
2012 | 2011 | 2012 | 2011 | |||||||||||||
Revenue: | ||||||||||||||||
Business services | $ | 112,581 | $ | 89,293 | $ | 408,496 | $ | 312,768 | ||||||||
Implementation and other | 3,723 | 3,219 | 13,775 | 11,299 | ||||||||||||
Total revenue | 116,304 | 92,512 | 422,271 | 324,067 | ||||||||||||
Expense: | ||||||||||||||||
Direct operating | 45,208 | 34,810 | 166,886 | 122,795 | ||||||||||||
Selling and marketing | 27,580 | 23,235 | 104,300 | 79,775 | ||||||||||||
Research and development | 9,263 | 6,957 | 33,792 | 23,343 | ||||||||||||
General and administrative | 14,952 | 13,405 | 57,025 | 48,711 | ||||||||||||
Depreciation and amortization | 7,677 | 4,826 | 25,641 | 16,710 | ||||||||||||
Total expense | 104,680 | 83,233 | 387,644 | 291,334 | ||||||||||||
Operating income | 11,624 | 9,279 | 34,627 | 32,733 | ||||||||||||
Other income (expense) | 17 | 49 | 251 | 147 | ||||||||||||
Income before income tax provision | 11,641 | 9,328 | 34,878 | 32,880 | ||||||||||||
Income tax provision | (5,701 | ) | (3,999 | ) | (16,146 | ) | (13,834 | ) | ||||||||
Net income | $ | 5,940 | $ | 5,329 | $ | 18,732 | $ | 19,046 | ||||||||
Net income per share - Basic | $ | 0.16 | $ | 0.15 | $ | 0.52 | $ | 0.54 | ||||||||
Net income per share - Diluted | $ | 0.16 | $ | 0.15 | $ | 0.50 | $ | 0.53 | ||||||||
Weighted average shares used in computing net income per share: | ||||||||||||||||
Basic | 36,264 | 35,392 | 35,956 | 35,046 | ||||||||||||
Diluted | 37,420 | 36,492 | 37,133 | 36,050 | ||||||||||||
5
athenahealth, Inc.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in thousands)
Year Ended December 31, | ||||||||
2012 | 2011 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
Net income | $ | 18,732 | $ | 19,046 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
Depreciation and amortization | 29,144 | 19,030 | ||||||
Amortization of premium on investments | 1,270 | 1,579 | ||||||
Provision for uncollectible accounts | 153 | 1,122 | ||||||
Excess tax benefit from stock-based awards | (14,179 | ) | (14,208 | ) | ||||
Deferred income tax | (890 | ) | (2,962 | ) | ||||
Change in fair value of contingent considerations | (5,118 | ) | 40 | |||||
Stock-based compensation expense | 27,236 | 18,901 | ||||||
Other reconciling adjustments | (178 | ) | 73 | |||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | (12,764 | ) | (12,130 | ) | ||||
Prepaid expenses and other current assets | 12,096 | 11,787 | ||||||
Other long-term assets | 111 | 489 | ||||||
Accounts payable | 13 | 688 | ||||||
Accrued expenses | 3,898 | 2,832 | ||||||
Accrued compensation | 7,959 | 8,055 | ||||||
Deferred revenue | 2,969 | 9,987 | ||||||
Deferred rent | (239 | ) | (3,565 | ) | ||||
Net cash provided by operating activities | 70,213 | 60,764 | ||||||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
Capitalized software development costs | (15,657 | ) | (7,779 | ) | ||||
Purchases of property and equipment | (23,904 | ) | (16,696 | ) | ||||
Proceeds from sales and disposals of property and equipment | 172 | — | ||||||
Proceeds from sales and maturities of investments | 160,340 | 168,083 | ||||||
Purchases of short-term and long-term investments | (118,919 | ) | (165,657 | ) | ||||
Payments on acquisition | (5,798 | ) | (34,882 | ) | ||||
Decrease in restricted cash | 3,650 | 3,684 | ||||||
Net cash used in investing activities | (116 | ) | (53,247 | ) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
Proceeds from issuance of common stock under stock plans and warrants | 18,699 | 14,097 | ||||||
Taxes paid related to net share settlement of restricted stock awards | (4,248 | ) | — | |||||
Excess tax benefit from stock-based awards | 14,179 | 14,208 | ||||||
Payment of contingent consideration accrued at acquisition date | (1,550 | ) | (3,355 | ) | ||||
Financing fee for line of credit | — | (741 | ) | |||||
Payment to terminate interest rate derivative contract | — | (563 | ) | |||||
Payments on long-term debt and capital lease obligations | — | (9,216 | ) | |||||
Net cash provided by financing activities | 27,080 | 14,430 | ||||||
Effects of exchange rate changes on cash and cash equivalents | 30 | (110 | ) | |||||
Net increase in cash and cash equivalents | 97,207 | 21,837 | ||||||
Cash and cash equivalents at beginning of period | 57,781 | 35,944 | ||||||
Cash and cash equivalents at end of period | $ | 154,988 | $ | 57,781 | ||||
Non-cash transactions | ||||||||
Property, equipment and purchased software recorded in accounts payable and accrued expenses | $ | 4,217 | $ | 8,066 | ||||
Taxes to be paid related to net share settlement of restricted stock awards in accrued exp. | $ | 258 | $ | — | ||||
Tax benefit recorded in prepaid expenses and other current assets | $ | 14,150 | $ | 13,803 | ||||
Cash received for interest | $ | 1,960 | $ | 1,900 | ||||
Cash paid for taxes | $ | 3,932 | $ | 2,708 | ||||
6
athenahealth, Inc.
STOCK-BASED COMPENSATION
(Unaudited, in thousands)
Set forth below is a breakout of stock-based compensation impacting the Consolidated Statements of Income for the three and twelve months ended December 31, 2012 and 2011:
Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||||
2012 | 2011 | 2012 | 2011 | ||||||||||||
Stock-based compensation charged to Consolidated Statements of Income: | |||||||||||||||
Direct operating | $ | 1,547 | $ | 948 | $ | 5,619 | $ | 3,173 | |||||||
Selling and marketing | 2,312 | 1,721 | 7,717 | 5,645 | |||||||||||
Research and development | 306 | 815 | 3,213 | 2,311 | |||||||||||
General and administrative | 2,553 | 2,385 | 10,687 | 7,772 | |||||||||||
Total stock-based compensation expense | 6,718 | 5,869 | 27,236 | 18,901 | |||||||||||
Amortization of capitalized stock-based compensation related to software development (1) | 257 | — | 257 | — | |||||||||||
Total | $ | 6,975 | $ | 5,869 | $ | 27,493 | $ | 18,901 | |||||||
(1) | In addition, for the three and twelve months ended December 31, 2012, $0.8 million of stock-based compensation was capitalized in the line item Capitalized Software Costs in the Consolidated Balance Sheet for which $0.3 million of amortization was included in the line item Depreciation and Amortization Expense in the Consolidated Statements of Income. The amount of stock-based compensation related to capitalized software development costs in prior periods was not significant. |
athenahealth, Inc.
CASH, CASH EQUIVALENTS, AND AVAILABLE-FOR-SALE INVESTMENTS
(Unaudited, in thousands)
Set forth below is a breakout of total cash, cash equivalents, and available-for-sale investments as of December 31, 2012, and December 31, 2011:
December 31, 2012 | December 31, 2011 | ||||||
Cash, cash equivalents | $ | 154,988 | $ | 57,781 | |||
Short-term investments | 38,092 | 62,084 | |||||
Long-term investments (1) | — | 18,619 | |||||
Total | $ | 193,080 | $ | 138,484 | |||
(1) | The Company has purchased certain available-for-sale investments that had a maturity date longer than one-year, which it classifies in “Investments and other assets” on the consolidated balance sheet. |
7
athenahealth, Inc.
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
TO COMPARABLE GAAP MEASURES
(Unaudited, in thousands, except per share amounts)
The following is a reconciliation of the non-GAAP financial measures used by the Company to describe the Company’s financial results determined in accordance with accounting principles generally accepted in the United States of America (GAAP). An explanation of these measures is also included below under the heading “Explanation of Non-GAAP Financial Measures.”
While management believes that these non-GAAP financial measures provide useful supplemental information to investors regarding the underlying performance of the Company’s business operations, investors are reminded to consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. In addition, it should be noted that these non-GAAP financial measures may be different from non-GAAP measures used by other companies, and management may utilize other measures to illustrate performance in the future. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with the Company’s results of operations as determined in accordance with GAAP.
Please note that these figures may not sum exactly due to rounding.
Non-GAAP Adjusted Gross Margin
Set forth below is a presentation of the Company’s “Non-GAAP Adjusted Gross Profit” and “Non-GAAP Adjusted Gross Margin,” which represents Non-GAAP Adjusted Gross Profit as a percentage of total revenue.
(unaudited, in thousands) | Three Months Ended | Twelve Months Ended | |||||||||||||
December 31, | December 31, | ||||||||||||||
2012 | 2011 | 2012 | 2011 | ||||||||||||
Total revenue | $ | 116,304 | $ | 92,512 | $ | 422,271 | $ | 324,067 | |||||||
Direct operating expense | 45,208 | 34,810 | 166,886 | 122,795 | |||||||||||
Total revenue less direct | |||||||||||||||
operating expense | 71,096 | 57,702 | 255,385 | 201,272 | |||||||||||
Add: Stock-based compensation | |||||||||||||||
allocated to direct operating expense | 1,547 | 948 | 5,619 | 3,173 | |||||||||||
Add: Amortization of purchased intangibles | 1,100 | 761 | 3,359 | 2,230 | |||||||||||
Non-GAAP Adjusted Gross Profit | $ | 73,743 | $ | 59,411 | $ | 264,363 | $ | 206,675 | |||||||
Non-GAAP Adjusted Gross Margin | 63.4 | % | 64.2 | % | 62.6 | % | 63.8 | % | |||||||
8
Non-GAAP Adjusted EBITDA
Set forth below is a reconciliation of the Company’s “Non-GAAP Adjusted EBITDA” and “Non-GAAP Adjusted EBITDA Margin,” which represents Non-GAAP Adjusted EBITDA as a percentage of total revenue.
(unaudited, in thousands) | Three Months Ended | Twelve Months Ended | |||||||||||||
December 31, | December 31, | ||||||||||||||
2012 | 2011 | 2012 | 2011 | ||||||||||||
Total Revenue | $ | 116,304 | $ | 92,512 | $ | 422,271 | $ | 324,067 | |||||||
GAAP net income | 5,940 | 5,329 | 18,732 | 19,046 | |||||||||||
Add: Provision for income taxes | 5,701 | 3,999 | 16,146 | 13,834 | |||||||||||
Less: Total other income | (17 | ) | (49 | ) | (251 | ) | (147 | ) | |||||||
Add: Stock-based compensation expense | 6,718 | 5,869 | 27,236 | 18,901 | |||||||||||
Add: Depreciation and amortization | 7,677 | 4,826 | 25,641 | 16,710 | |||||||||||
Add: Amortization of purchased intangibles | 1,100 | 761 | 3,359 | 2,230 | |||||||||||
Non-GAAP Adjusted EBITDA | $ | 27,119 | $ | 20,735 | $ | 90,863 | $ | 70,574 | |||||||
Non-GAAP Adjusted EBITDA Margin | 23.3 | % | 22.4 | % | 21.5 | % | 21.8 | % | |||||||
Non-GAAP Adjusted Operating Income
Set forth below is a reconciliation of the Company’s “Non-GAAP Adjusted Operating Income” and “Non-GAAP Adjusted Operating Income Margin,” which represents Non-GAAP Adjusted Operating Income as a percentage of total revenue.
(unaudited, in thousands) | Three Months Ended | Twelve Months Ended | |||||||||||||
December 31, | December 31, | ||||||||||||||
2012 | 2011 | 2012 | 2011 | ||||||||||||
Total revenue | $ | 116,304 | $ | 92,512 | $ | 422,271 | $ | 324,067 | |||||||
GAAP net income | 5,940 | 5,329 | 18,732 | 19,046 | |||||||||||
Add: Provision for income taxes | 5,701 | 3,999 | 16,146 | 13,834 | |||||||||||
Less: Total other income | (17 | ) | (49 | ) | (251 | ) | (147 | ) | |||||||
Add: Stock-based compensation expense | 6,718 | 5,869 | 27,236 | 18,901 | |||||||||||
Add: Amortization of capitalized stock-based compensation related to software development | 257 | — | 257 | — | |||||||||||
Add: Amortization of purchased intangibles | 1,100 | 761 | 3,359 | 2,230 | |||||||||||
Non-GAAP Adjusted Operating Income | $ | 19,699 | $ | 15,909 | $ | 65,479 | $ | 53,864 | |||||||
Non-GAAP Adjusted Operating Income Margin | 16.9 | % | 17.2 | % | 15.5 | % | 16.6 | % | |||||||
9
Non-GAAP Adjusted Net Income
Set forth below is a reconciliation of the Company’s “Non-GAAP Adjusted Net Income” and “Non-GAAP Adjusted Net Income per Diluted Share.”
(unaudited, in thousands) | Three Months Ended | Twelve Months Ended | |||||||||||||
December 31, | December 31, | ||||||||||||||
2012 | 2011 | 2012 | 2011 | ||||||||||||
GAAP net income | $ | 5,940 | $ | 5,329 | $ | 18,732 | $ | 19,046 | |||||||
Add: Loss on interest rate derivative contract | — | — | — | 73 | |||||||||||
Add: Stock-based compensation expense | 6,718 | 5,869 | 27,236 | 18,901 | |||||||||||
Add: Amortization of capitalized stock-based compensation related to software development | 257 | — | 257 | — | |||||||||||
Add: Amortization of purchased intangibles | 1,100 | 761 | 3,359 | 2,230 | |||||||||||
Sub-total of tax deductible items | 8,075 | 6,630 | 30,852 | 21,204 | |||||||||||
(Less): Tax impact of tax deductible items (1) | (3,230 | ) | (2,652 | ) | (12,341 | ) | (8,482 | ) | |||||||
Non-GAAP Adjusted Net Income | $ | 10,785 | $ | 9,307 | $ | 37,243 | $ | 31,768 | |||||||
Weighted average shares - diluted | 37,420 | 36,492 | 37,133 | 36,050 | |||||||||||
Non-GAAP Adjusted Net Income per Diluted Share | $ | 0.29 | $ | 0.26 | $ | 1.00 | $ | 0.88 | |||||||
(1) | Tax impact calculated using a statutory tax rate of 40%. |
(unaudited, in thousands) | Three Months Ended | Twelve Months Ended | |||||||||||||
December 31, | December 31, | ||||||||||||||
2012 | 2011 | 2012 | 2011 | ||||||||||||
GAAP net income per share - diluted | $ | 0.16 | $ | 0.15 | $ | 0.50 | $ | 0.53 | |||||||
Add: Loss on interest rate derivative contract | — | — | — | — | |||||||||||
Add: Stock-based compensation expense | 0.18 | 0.16 | 0.73 | 0.52 | |||||||||||
Add: Amortization of capitalized stock-based compensation related to software development | 0.01 | — | 0.01 | — | |||||||||||
Add: Amortization of purchased intangibles | 0.03 | 0.02 | 0.09 | 0.06 | |||||||||||
Sub-total of tax deductible items | 0.22 | 0.18 | 0.83 | 0.59 | |||||||||||
(Less): Tax impact of tax deductible items (1) | (0.09 | ) | (0.07 | ) | (0.33 | ) | (0.24 | ) | |||||||
Non-GAAP Adjusted Net Income per Diluted Share | $ | 0.29 | $ | 0.26 | $ | 1.00 | $ | 0.88 | |||||||
Weighted average shares - diluted | 37,420 | 36,492 | 37,133 | 36,050 | |||||||||||
(1) | Tax impact calculated using a statutory tax rate of 40%. |
10
Explanation of Non-GAAP Financial Measures
The Company reports its financial results in accordance with accounting principles generally accepted in the United States of America, or GAAP. However, management believes that, in order to properly understand the Company’s short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash or non-recurring items, when used as a supplement to financial performance measures in accordance with GAAP. These items result from facts and circumstances that vary in frequency and impact on continuing operations. Management also uses results of operations before such items to evaluate the operating performance of the Company and compare it against past periods, make operating decisions, and serve as a basis for strategic planning. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in the Company’s ongoing business by eliminating certain non-cash expenses and other items that management believes might otherwise make comparisons of the Company’s ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management’s ability to make useful forecasts. Management believes that these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing the Company’s financial and operational performance and comparing this performance to its peers and competitors.
Management defines “Non-GAAP Adjusted Gross Profit” as total revenue, less direct operating expense, plus (1) stock-based compensation expense allocated to direct operating expense and (2) amortization of purchased intangibles, and “Non-GAAP Adjusted Gross Margin” as Non-GAAP Adjusted Gross Profit as a percentage of total revenue. Management considers these non-GAAP financial measures to be important indicators of the Company’s operational strength and performance of its business and a good measure of its historical operating trends. Moreover, management believes that these measures enable investors and financial analysts to closely monitor and understand changes in the Company’s ability to generate income from ongoing business operations.
Management defines “Non-GAAP Adjusted EBITDA” as the sum of GAAP net income before provision for income taxes, total other (income) expense, stock-based compensation expense, depreciation and amortization, and amortization of purchased intangibles and “Non-GAAP Adjusted EBITDA Margin” as Non-GAAP Adjusted EBITDA as a percentage of total revenue. Management defines “Non-GAAP Adjusted Operating Income” as the sum of GAAP net income before provision for income taxes, total other (income) expense, stock-based compensation expense, amortization of capitalized stock-based compensation related to software development, and amortization of purchased intangibles, and “Non-GAAP Adjusted Operating Income Margin” as Non-GAAP Adjusted Operating Income as a percentage of total revenue. Management defines “Non-GAAP Adjusted Net Income” as the sum of GAAP net income before loss on interest rate derivative contract, stock-based compensation expense, amortization of capitalized stock-based compensation related to software development, amortization of purchased intangibles, and any tax impact related to these items, and “Non-GAAP Adjusted Net Income per Diluted Share” as Non-GAAP Adjusted Net Income divided by weighted average diluted shares outstanding. Management considers all of these non-GAAP financial measures to be important indicators of the Company’s operational strength and performance of its business and a good measure of its historical operating trends, in particular the extent to which ongoing operations impact the Company’s overall financial performance.
Management excludes each of the items identified below from the applicable non-GAAP financial measure referenced above for the reasons set forth with respect to that excluded item:
11
• | Stock-based compensation expense and amortization of capitalized stock-based compensation related to software development — excluded because these are non-cash expenditures that management does not consider part of ongoing operating results when assessing the performance of the Company’s business, and also because the total amount of the expenditure is partially outside of the Company’s control because it is based on factors such as stock price, volatility, and interest rates, which may be unrelated to the Company’s performance during the period in which the expense is incurred. |
• | Amortization of purchased intangibles — purchased intangibles are amortized over their estimated useful life and generally cannot be changed or influenced by management after the acquisition. Accordingly, this item is not considered by management in making operating decisions. Thus, including such charge does not accurately reflect the performance of the Company’s ongoing operations for the period in which such charge is incurred. |
• | Gains and losses on interest rate derivative contract — excluded because, until they are realized, to the extent these gains or losses impact a period presented, management does not believe that they reflect the underlying performance of ongoing business operations for such period. |
12